Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting ...Middle East

HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific...

Hence then, the article about akeso published mechanism of action for cldn18 2 cd47 bispecific antibody ak132 for the first time at sitc annual meeting was published today ( Friday 08/11/2024 - 03:33 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting )

Also on site :

• What the US strike in Venezuela means for gas prices and the largest proven oil reserve on the planet
• Ukraine-Russia war latest: Zelensky and Starmer discuss how to spend billions seized from Abramovich after Chelsea sale
• State of emergency declared: Venezuela mobilizes following US airstrikes